EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Specific phenotypes may drive an increased incidence of pediatric inflammatory bowel disease in South‐Eastern Norway

Svend Andersen iD, Tomm Bernklev, Ketil Størdal, Milada C Hagen, Vendel A Kristensen, Randi Opheim, Christine Olbjørn, Jon Rove, Emma E Løvlund, Hans K Holm, Batool Aballi, Marte L Høivik und 1 weitere

Journal of Pediatric Gastroenterology and Nutrition · 2025

DOI: 10.1002/jpn3.70148 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Svend Andersen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: South-Eastern Health Authorities in Norway, Takeda Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Tillots Pharma, and DAM Foundation, Takeda Pharmaceuticals; Pfizer; Ferring Pharmaceuticals; Tillots Pharma; DAM Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pediatric inflammatory bowel disease (PIBD) incidence has increased in recent decades but may be stabilizing, prompting exploration of incidence changes, disease distribution, and severity.

Methods

From 2017 to 2019, patients under 18 years with PIBD symptoms were recruited from nine hospitals in South‐Eastern Norway for Inflammatory Bowel Disease in South‐Eastern Norway III (IBSEN III), a population‐based inception cohort study. The primary outcome was a diagnosis of any PIBD subtype as defined by revised Porto criteria. Paris classification system defined disease phenotypes, and descriptions of covariates were gathered from patients in IBSEN III.

Results

We identified 324 PIBD patients, with 216 consenting to the IBSEN III study. The crude incidence rate was 17.8 per 100,000 person‐years (PY) (95% confidence interval [CI]: 15.9–19.8). Crohn's disease (CD) was found in 118 patients (54.6%); 48% had ileocolonic distribution, 40% had upper gastrointestinal disease, and 12.8% had perianal disease. Complications (stricturing and/or penetrating) were noted in 18%. Ulcerative colitis (UC) was diagnosed in 78 patients (36.1%), predominantly pancolitis (41%), with 30% having proctitis. One in five suffered severe disease. IBD unclassified was found in 20 patients (9.3%). PIBD incidence in those under 16 was 13.6/100,000 PY, up from 4.7 in the IBSEN study 27 years ago. Terminal ileitis (11%–23%) and proctitis (14%–25%) rose from IBSEN (1990–1993) to IBSEN III, while stricturing/penetrating disease changed insignificantly (17%–16%).

Conclusions

The incidence of PIBD has risen in South‐Eastern Norway, with increased cases of terminal ileitis in CD, unchanged stricturing/penetrating disease, and increased proctitis in UC compared to the original IBSEN study. Clinical Trial Registration ClinicalTrials.gov identifier: NCT02727959.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesAdolescentChildChild, PreschoolFemaleHumansInfantMaleCohort StudiesIncidenceNorwayPhenotypeSeverity of Illness Index

Stichwörter der Autor:innen

IBSEN IIIPCDAIPUCAIParis classificationpopulation‐based

Autor:innen und Institutionen

  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Medical Department, Vestfold Hospital Trust, Tønsberg, Norway.
  • Research Department, Vestfold Hospital Trust, Tønsberg, Norway.
  • Pediatric Department, Oslo University Hospital, Oslo, Norway.
  • Department of Pediatric Research, University of Oslo, Oslo, Norway.
  • Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.

ORCID-Profile: Svend Andersen

Förderung

  • South-Eastern Health Authorities in Norway
  • Takeda Pharmaceuticals, Pfizer, Ferring Pharmaceuticals, Tillots Pharma, and DAM Foundation
  • Takeda Pharmaceuticals; Pfizer; Ferring Pharmaceuticals; Tillots Pharma; DAM Foundation

Zitieren

APA

Andersen, S., Bernklev, T., Størdal, K., Hagen, M. C., Kristensen, V. A., Opheim, R., Olbjørn, C., Rove, J., Løvlund, E. E., Holm, H. K., Aballi, B., Høivik, M. L., & Perminow, G. (2025). Specific phenotypes may drive an increased incidence of pediatric inflammatory bowel disease in South‐Eastern Norway. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70148

Vancouver

Andersen S, Bernklev T, Størdal K, Hagen MC, Kristensen VA, Opheim R, et al. Specific phenotypes may drive an increased incidence of pediatric inflammatory bowel disease in South‐Eastern Norway. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70148

BibTeX
@article{Andersen2025,
  author = {Andersen, Svend and Bernklev, Tomm and Størdal, Ketil and Hagen, Milada C and Kristensen, Vendel A and Opheim, Randi and Olbjørn, Christine and Rove, Jon and Løvlund, Emma E and Holm, Hans K and Aballi, Batool and Høivik, Marte L and Perminow, Gøri},
  title = {Specific phenotypes may drive an increased incidence of pediatric inflammatory bowel disease in South‐Eastern Norway},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2025},
  doi = {10.1002/jpn3.70148}
}
Kostenlos starten →